Ascendis Pharma A (ASND) EBITDA Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted EBITDA Margin of 10.06% for Q1 2026, up 323.42% sequentially from 2.38% in Q4 2025, and up 11329.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Ascendis Pharma A (ASND) EBITDA Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported EBITDA Margin for 13 years, with the latest figure at 10.06% in Q1 2026.
- Quarterly EBITDA Margin rose 11329.0% year-over-year to 10.06% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.54% (down 7576475.0% YoY) and the FY2025 annual result came in at 18.92%, up 4978.0% from the prior year.
- EBITDA Margin improved to 10.06% in Q1 2026 per ASND's latest filing, from 2.38% in the prior quarter.
- Over five years, EBITDA Margin peaked at 123555.16% in Q4 2024 and troughed at 2303.46% in Q2 2022.
- A 5-year average of 6827.24% and a median of 167.28% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin jumped 12356726 bps in 2024, then plunged 12355279 bps in 2025.
- Over 5 years, EBITDA Margin stood at 643.75% in 2022, then soared by 98 bps to 12.09% in 2023, then surged by 1021723 bps to 123555.16% in 2024, then sank by 100 bps to 2.38% in 2025, then surged by 323 bps to 10.06% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 10.06%, 2.38%, and 5.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn | 64.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 64.98% |
| Mar 31, 2026 | 10.63% |
| Dec 31, 2025 | 6.47% |
| Sep 30, 2025 | 5.15% |
| Jun 30, 2025 | -33.50% |
| Mar 31, 2025 | -101.30% |
| Dec 31, 2024 | 3.05% |
| Sep 30, 2024 | -167.28% |
| Jun 30, 2024 | -370.18% |
| Mar 31, 2024 | -51.25% |
| Dec 31, 2023 | -23.49% |
| Sep 30, 2023 | -279.82% |
| Jun 30, 2023 | -297.17% |
| Mar 31, 2023 | -427.77% |
| Dec 31, 2022 | -567.25% |
| Sep 30, 2022 | -945.09% |
| Jun 30, 2022 | -2,303.46% |
| Mar 31, 2022 | -1,875.06% |
| Dec 31, 2021 | -113.36% |
| Sep 30, 2021 | -8,709.07% |